

# The Switching Antiplatelet-9 (SWAP-9) Study

NCT06588595

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 4
<b>Sponsor</b>	University of Florida
<b>Enrollment</b>	90 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Patients who have undergone PCI and are on maintenance treatment with DAPT, composed of low-dose aspirin (81mg qd) with either prasugrel (10 mg qd) or ticagrelor (90 mg bid). In particular, patients who underwent PCI in the setting of an acute coronary syndrome will be eligible for randomization after e90 days post-PCI, while patients who underwent PCI in the setting of a chronic coronary syndrome e30 days post-PCI.
- Age e18 years
- Provide written informed consent.

### Exclusion (8)

- Prior history of stent thrombosis
- PCI within 30 days
- On treatment with any oral anticoagulant (vitamin K antagonists, dabigatran, rivaroxaban, apixaban, edoxaban) or chronic low-molecular-weight heparin (at venous thrombosis treatment, not for prophylaxis)
- Hemodynamic instability
- Hypersensitivity to clopidogrel
- ... and 3 more (see full listing online)

## Locations (1 total)

---

University of Florida, Jacksonville, Florida, United States